Search
Life Sciences
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory Approvals in EU and UK for Phase 1b Studies
Company Secures Additional Financing...
Allozymes, a leading innovator in the discovery and engineering of enzymes (proteins acting as catalysts in all living organisms) for the food and chemical industries, has...
Tubulis announced today that Fierce Biotech has named the company as one of 2024’s “Fierce 15” biotechnology companies. The annual special report features the most...
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announces the successful completion of...
Tubulis announced today that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation to its lead antibody-drug conjugate (ADC) TUB-040 for the...
Tubulis announced today that the first patient has been treated in its first Phase I/IIa trial. The study is evaluating Tubulis’ next-generation antibody-drug conjugate (ADC)...
Source : La Gazette du LABORATOIRE
©LaGazetteDuLABORATOIRE
Starfish Bioscience aims to provide microbiological solutions to restore the soil microbiome for...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to...
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.
